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BACKgroUnD
Although the burden of skin disease—
the totality of the health, social, and 
economic consequences—is vast, it is 
important to quantify it because of its 
implications for allocating research sup-
port and clinical care resources, as well 
as for the public perception of skin dis-
ease. Accordingly, the approach or pro-
cess for estimating the burden requires 
a rigorous and systematic methodol-
ogy to accurately quantify its volume, 
the number of skin conditions, costs 
of treatment, and the degree to which 
a disease impedes daily life in both the 
public and the private domains.
As part of the National Institutes of 
Health fiscal year 2002 appropriations, 
Congress requested that the National 
Institute of Arthritis and Musculoskeletal 
and Skin Diseases (NIAMS), in col-
laboration with other federal agencies 
and voluntary health and professional 
organizations, assess the burden of skin 
disease. In response to the request, the 
NIAMS sponsored the Workshop on the 
Burden of Skin Diseases in September 
2002 to discuss elements that comprise 
the burden of skin diseases and their 
impact on public health and daily liv-
ing. The primary goals were to: (1) deter-
mine the range of issues that needed to 
be considered in examining the burden 
of skin disease and (2) describe available 
data and data-collection instruments that 
could be used in assessing the burden. 
As part of this process, workshop partici-
pants considered current knowledge and 
data-collection instruments, means to 
access data more effectively, and future 
needs and instruments for facilitating the 
collection of needed data.
Participants concluded that there 
was a lack of adequate instruments 
and sources of information to measure 
accurately the prevalence, economic 
cost, and quality of life (QOL) from 
both a patient and a societal perspec-
tive. Workshop participants recom-
mended that core measures of the bur-
den of skin disease be developed to 
address general, skin-specific, and skin 
disease–specific issues.
Based on the workshop participants’ 
recommendations, a working group 
was established to survey existing data 
sets and available instruments for their 
potential to estimate components of the 
burden of skin disease. These sources of 
data were evaluated for their capacity 
to provide information on general skin 
disease, specific skin diseases, and dis-
ease impact from the personal, family, 
and societal perspectives.
This report summarizes the efforts 
of this working group and details the 
methodology, sources of information, 
findings, and recommendations put 
forth by the project team. It is struc-
tured as three perspectives based on 
the conceptual framework of disease 
burden as conceptualized by the core 
project team. The NIAMS project, 
Core Measures of the Burden of Skin 
Diseases, is described in the upcoming 
NIAMS report.
generAL metHoDS
A core team, consisting of two der-
matologists with expertise in health 
services research (SC) and epidemiol-
ogy (MVB), a survey design expert (SB), 
a health economist (LB), and a health 
policy analyst (JB), developed the meth-
odological approach with input from 
ad hoc experts in the fields of clinical 
epidemiology and dermatology (MW 
and DM), dermatologic health services 
research (MMC), pediatric dermato-
logic health services research (SC), cost 
of illness (TH), and health economic 
QOL measures (GT). The methodologi-
cal approach entailed (1) establishing 
the conceptual framework and working 
definitions, (2) identifying the sources 
of information, (3) deriving structured 
queries to assess the sources of infor-
mation, and (4) qualitatively assessing 
the information sources. Information 
was compiled via (1) known sources 
based on prior research and work expe-
rience in a variety of federal agencies, 
(2) literature reviews, (3) comprehen-
sive Internet and medical searches, and 
(4) comments from the ad hoc experts 
upon review of the information com-
piled by the core team. Journal articles 
were reviewed for citations of other 
relevant studies and structured queries 
were derived a priori to systematically 
evaluate each source of information.
Conceptual framework and definitions
A conceptual framework for the 
burden of skin disease was mod-
eled after methodology of the Global 
Burden of Disease Study supported 
by the World Bank and the World 
Health Organization (WHO) (Lopez 
and Murray, 1998). The WHO study 
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described the determinants of burden 
as epidemiology (incidence, preva-
lence, and mortality), costs, and QOL 
impact. In order to apply an econom-
ic approach to QOL, we included 
patient preference measures (utilities 
and willingness to pay) in this frame-
work. Definitions for key terms, such 
as skin disease, epidemiology, costs, 
and QOL, were discussed a priori in 
this project.
Definition of skin disease. The 
term “skin disease” has been defined 
in the NIAMS Dermatology Lexicon 
Project, the Cochrane Classification, 
and the joint American Academy 
of Dermatology (AAD)–Society for 
Investigative Dermatology (SID) short 
list of the 22 most common derma-
tological diseases. Definitions have 
also been given in guidelines by the 
AAD (“Practice of Dermatology”) and 
the NIAMS (“Cutaneous Science”).  
The first three approaches represent 
research endeavors with varying goals, 
each requiring a priori definition of skin 
disease. The “Practice of Dermatology” 
defines the realm of dermatology as 
skin disorders treated by dermatolo-
gists. Unfortunately, this definition 
excludes skin disorders that may not 
usually present to dermatologists, such 
as diabetic foot ulcers and thermal 
burns. While all the guidelines have 
systematically derived a classification 
system for dermatology diseases, each 
differs in charge, and none is compre-
hensive. We chose to use the NIAMS 
“Cutaneous Science” definition of skin 
disease—any disease or condition that 
affects the skin—because it appeared 
to be the least restrictive, allowing for 
the most comprehensive estimate of 
burden. Within this definition, the team 
also differentiated skin diseases that 
are comorbidities or complications of 
systemic disorders from skin diseases 
without systemic implications.
The “Cutaneous Science” defini-
tion was the best fit for the philosophy 
behind the project, but a more prac-
tical approach was necessary when 
evaluating the sources of information 
used to estimate the burden of skin dis-
ease. The core team derived a “short 
list” of skin diseases that included the 
list compiled by the AAD–SID joint 
project (Bickers et al., 2006) of the 22 
most common skin diseases, along 
with additional entities known to be 
included in existing national survey 
databases and in existing literature on 
health-related QOL.
Definition of epidemiology. Clas-
sically, epidemiology has been indexed 
by four metrics: (1) incidence, (2) point 
prevalence, (3) period prevalence, and 
(4) mortality. Each metric has its own 
strengths and weaknesses in reflecting 
disease burden. For the purpose of this 
project, the epidemiological construct 
of burden was meant to capture the vol-
ume and persistence of skin disease in 
the United States. Each of the specific 
epidemiological metrics may be more 
or less appropriate for a specific disease 
when attempting to measure burden. 
For example, in the case of a transient 
disease, many may have suffered from 
the disease over time but with only a 
few having the disease at one point in 
time. Because point or period preva-
lence measures the number who have 
the disease at one point or during one 
period in time, the true volume of a tran-
sient disease may be underestimated. 
Thus, the volume metric of a transient 
disease might best be expressed by the 
incidence of that condition over an 
extended period of time. In our method-
ological approach, we included all four 
metrics of epidemiology.
Definition of quality of life. QOL is 
impacted by a variety of factors, includ-
ing the physical and social environ-
ment, sovereignty, financial security, 
and health. These domains are intri-
cately related. However, when con-
sidering burden of disease, the health 
domain is the most pertinent aspect of 
QOL and the one on which this study 
focused. The definition of QOL for the 
project took into the account the terms 
used by the WHO. In the WHO nomen-
clature, “impairment,” “disability,” and 
“handicap” represent symptoms, func-
tional impact, and broad psychological, 
social, and emotional impact, respec-
tively. Because dermatological diseas-
es can impact all three constructs, the 
project team included all three in the 
concept of QOL. The project team also 
distinguished health-status measures 
from utilities as two distinct but relat-
ed ways to measure QOL. Like “skin 
disease,” QOL has been defined and 
operationalized in a variety of ways, and 
there is controversy among researchers 
as to exactly what should and should 
not be included in its definition. This is 
reflected in the variety of approaches to 
QOL assessment adopted in the instru-
ments reviewed.
Health-status measures address QOL 
by representing the three constructs 
defined above in a comprehensive 
manner. Health-status measures can 
address QOL from general health, skin-
specific, or disease-specific perspec-
tives. The more general the measure, 
the more applicable the instrument is 
across different diseases and popula-
tions. However, in contrast to disease-
specific measures, the general mea-
sures are less sensitive to issues specific 
to the individual skin disease.
Patient preferences are an alternative 
means of addressing QOL. Health utili-
ties are one such measure that involves 
asking the patient to imagine giving up 
some interval of a lifetime to have per-
fect health or accepting a certain risk of 
death to obtain perfect health. A related 
measure is the willingness to pay, which 
quantifies patient preferences as a dol-
lar amount. The advantage of the util-
ity and willingness-to-pay approach is 
that it reflects patient preferences, thus 
offering a unique approach to capturing 
a summary measure of costs.
Definition of costs. Spurred by the 
rapid growth of domestic health-care 
expenditures, medical researchers have 
conducted numerous studies aimed at 
measuring the economic costs of partic-
ular diseases or illnesses. Historically, 
“cost of illness” has referred to the 
opportunity costs associated with the 
direct costs of medical care, the indi-
rect costs of lost productivity due to 
morbidity and mortality, and the intan-
gible costs of pain and suffering. The 
perspective of the analysis significantly 
affects the types of costs included in 
cost-of-illness studies. Common per-
spectives include those of the patient, 
health-care facility, third-party payer, 
and society. Each of these perspectives 
differs substantially with respect to 
the type and volume of costs included 
in the analysis. For purposes of this 
project, we consider the costs of skin 
disease as including all costs associ-
ated with the illnesses that affect only 
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skin, as well as those that originate in 
skin but subsequently affect other areas 
of the body (e.g., cutaneous melanoma) 
or are a consequence of adverse events 
to either skin or non-skin areas stem-
ming from medical treatments for skin 
disease (e.g., psoriasis treatment). For 
illnesses that initiate with other tissues 
or organs but subsequently cause skin 
disease (e.g., AIDS, diabetic ulcer), we 
include only the skin-related treatment 
costs. In instances of non-skin-related 
conditions that necessitate more expen-
sive medical treatment due to concur-
rent skin disease, we count only those 
incremental costs.
Summary
The following sections are organized 
according to the constructs of burden 
of disease: epidemiology, health-status 
QOL, preference-based QOL, and cost 
burden. The methodology common to 
each construct has been previously dis-
cussed; construct-specific methods and 
results are presented as follows.
epiDemioLogY
methods
The goal of the review and summary of 
each pertinent database was to provide 
an assessment of the dependability of 
data elements relating to skin disease 
and the durability of such data sources 
for their potential use in estimating the 
epidemiologic burden of skin disease 
in the United States. Such information 
was gathered from websites, publica-
tions, and telephone interviews with 
personnel working with each database. 
Potential sources of epidemiologic 
information were explored and evalu-
ated for point and period prevalence, 
incidence, mortality, and content qual-
ity and validity. Each source was sys-
tematically examined for potential use 
in determining population estimates of 
skin disease. Advantages and disadvan-
tages of using data from these sources 
as an estimate of the epidemiologic 
burden are discussed here and detailed 
in the NIAMS report.
Definition of public and private 
databases. Publicly available databases 
were defined as those that offer access 
to data files for a nominal fee or free of 
charge. Private databases were defined 
as those maintained by private compa-
nies that are not available to the pub-
lic or are proprietary. The list of private 
databases in the NIAMS report is not 
intended to be exhaustive; they were 
chosen to be representative of exist-
ing institutions that maintain private 
databases (e.g., health maintenance 
organizations and indemnity insurance 
companies). The databases on the ulti-
mate list were selected on the basis of 
several factors, including the ability 
to identify a contact person within the 
private institution who was capable of 
answering the questions in our struc-
tured query, the cost of obtaining rep-
resentative data, and the willingness of 
the institution to discuss the database 
with a member of the core team.
Structured query to assess data 
sources. Items included in the struc-
tured query include a priori intent of the 
database, managing agency, ascertain-
ment methodology, type of information 
collected, quality assurance, validity of 
the data as a reflection of true popula-
tion statistics, use in the published liter-
ature, and potential value for estimating 
the epidemiologic, QOL, or economic 
burden of skin disease. Such informa-
tion was gathered from websites, litera-
ture searches, publications, and tele-
phone interviews with personnel who 
had access to each database.
results
More than 60 public databases were 
reviewed from the above-mentioned 
sources. Of these, 22 databases 
(Supplementary Table S1 online) con-
tained information pertaining to an epi-
demiologic metric of skin disease. The 
22 public databases and 6 private data-
bases are summarized in Table S1 along 
with a list of the pertinent published 
literature derived from each database 
and an assessment of its potential value 
for estimating the epidemiologic, QOL, 
and economic burden of skin disease.
Although many databases purport to 
capture the incidence of skin disease, 
very few do so accurately because they 
rely on the International Classification 
of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes as 
data points. These codes were designed 
for billing purposes and do not delin-
eate whether the diagnosis is new or 
pre-existing; they therefore cannot 
discriminate between incidence and 
prevalence. Moreover, there is inherent 
risk for significant misclassification bias 
when using ICD-9 codes for epidemio-
logical data, because such codes are 
intended to capture health-utilization 
information, not epidemiologic infor-
mation.
Among the public databases, only 
the Surveillance, Epidemiology, and 
End Results program tracks the inci-
dence of cancer, survival, and mortality, 
and the scope of diagnoses is limited to 
specific cancers of the skin (melanoma 
and lymphoma). Among the private 
databases evaluated, only the Rochester 
Epidemiology project captures diagno-
ses using a unique medical diagnoses 
index for every patient encounter.
We found four public databases that 
collected information via surveys that 
queried patients about the presence of 
a skin condition. If a survey study base 
is representative of the general popula-
tion, such data are amenable to estimat-
ing population prevalence. However, 
the inability of a subject to categorize 
or self-diagnose skin disease accurately 
may result in misclassification bias.
Public databases have several advan-
tages: accessibility of data, transpar-
ency of internal quality assessment, 
and size of the represented population. 
However, many of the U.S. public data-
bases reviewed for this project repre-
sent very different populations. Such 
variations in population base greatly 
complicate the ability to compare or 
validate prevalence rates from one 
database to another.
An exhaustive review of the pub-
lished literature on the epidemiology 
of skin disease revealed a paucity of 
studies based in the United States com-
pared with foreign sources. This may 
result in part from the relative ease of 
establishing and maintaining a compre-
hensive national health-care database 
in the presence of a national health-
care system. Nonetheless, it would be 
methodologically unsound to validate 
incidence or prevalence rates of skin 
disease within the United States with 
data from another country, because the 
epidemiologic burden of skin disease 
may differ substantially from country to 
country. Differences in a population’s 
genetic composition and economic 
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status, as well as in climate and other 
environmental and biological expo-
sures, frequently modify disease risk 
and subsequent burden across politi-
cal and geographical borders. Similarly, 
criteria and disease definitions are not 
uniform across the globe. Despite the 
limitations inherent in any cross-coun-
try comparison of data, national health-
care databases from other countries 
often provide excellent models for the 
rigorous methodology and comprehen-
siveness necessary for measuring the 
true epidemiologic burden in a popu-
lation. Future recommendations for 
establishing a system to track prospec-
tively the epidemiologic burden of skin 
disease within the United States must 
consider how our international col-
leagues have done this effectively for 
decades.
HeALtH-StAtUS QUALitY oF LiFe
methods
The QOL burden of skin disease as 
captured by health-status measures 
was designed to capture the symptom, 
functional, psychological, social, and 
emotional impact of these diseases on 
patients. The goal of the review and 
summary of published QOL instruments 
was to examine the construction and 
validity of available instruments and 
to assess the durability of each QOL 
instrument for potential use in estimat-
ing the QOL burden of skin disease in 
the United States. Each instrument was 
examined for conceptualization and 
definition of the “quality of life” con-
struct, evaluation of item development 
procedures, psychometric testing, psy-
chometric analyses, and perspective of 
QOL impact (adult, child, and family). 
The instruments were separated into 
three groups: (1) general health instru-
ments that have been applied to der-
matological diseases, (2) skin-specific 
QOL instruments, and (3) skin disease–
specific QOL instruments. A further dis-
tinction was made if the instrument was 
meant to be administered to children or 
families of patients.
Identifying health-status quality 
of life instruments. QOL instruments 
were identified with the above-outlined 
methodology. The list does not include 
instruments originally developed in lan-
guages other than English, instruments 
published in abstracts only, or those not 
publicly available. Subsequent citation 
counts were located using the search 
strategies described above and do not 
include abstracts or the original source 
reference. A summary overview and 
evaluation of the health-status QOL 
instruments for adults, children, and 
families are presented in Table S2.
Structured query for health-sta-
tus quality of life instruments. Items 
involved in the structured query were 
classified into those involving a general 
description of the instrument, the pur-
pose of the instrument, how the instru-
ment was developed, availability and 
cost to use, psychometric properties, 
quality assessment, translation, and sub-
sequent usage by other investigators.
results
Table S2 provides an overall summary 
of the 40 health-status QOL measure-
ment instruments that were identified 
for skin disease. The table provides 
descriptive information, including the 
original population on which it was 
used, the country of origin, the QOL 
constructs assessed, and the number of 
items. The types of psychometric test-
ing and validation that have been con-
ducted are also presented, along with 
information about the instrument’s sub-
sequent adoption by other researchers. 
We found a total of 11 adult skin-spe-
cific instruments, 15 adult disease-spe-
cific instruments, and 6 general health 
instruments that have been applied to 
skin disorders in adults.
There are currently far fewer instru-
ments focused on QOL for children 
with skin disease. We were able to 
locate only one skin-specific instru-
ment for children, two skin disease–
specific instruments, and only two 
generic health-status measures for 
children. QOL instruments that cap-
ture the family impact of skin disease 
were even fewer—three skin disease–
specific instruments. We were unable 
to locate any skin-specific or generic 
family-impact QOL instruments for 
skin disease.
Overall, there is a lack of standard-
ization in definitions and concep-
tualizations of QOL and how these 
conceptual frameworks have been 
translated into measurement instru-
ments. There is some consensus that, at 
a minimum, QOL incorporates percep-
tion of physical symptoms, effects on 
daily role functioning, and psychologic 
impact. However, there are disagree-
ment and confusion in the broader 
medical literature as to the precise defi-
nition, with researchers often using the 
same term (quality of life) to mean very 
different things. The same is true in the 
dermatologic literature.
Widely varying procedures have 
been used for the initial development of 
QOL measures for skin-disease popula-
tions. The amount and quality of psy-
chometric testing and validation also 
differ widely across instruments. Finally, 
the sophistication of the statistical pro-
cedures for psychometric testing varies. 
Two areas in which improved analytic 
techniques are needed are test–retest 
reliability and responsiveness. The intra-
class correlation coefficient is superior 
to the Pearson correlation coefficient 
in the test–retest situation for continu-
ous variables (i.e., scale scores), but it 
is rarely reported (Pearson correlations 
are typical). In responsiveness analyses, 
researchers rely predominantly on sim-
ple statistical significance tests, which 
at a minimum should be supplemented 
with summary measure(s) of effect size, 
standardized response mean, or rela-
tive efficiency.
Less than half of the 40 instruments 
reviewed here were initially devel-
oped in the United States. Instruments 
developed in other countries, such as 
the United Kingdom, may have impli-
cations for the appropriateness of the 
wording of specific items and thus 
may have limited applicability in the 
United States. There is a need for fur-
ther domestic application and testing 
of those instruments developed outside 
the United States.
preFerenCe-BASeD QUALitY oF LiFe
methods
The preference-based QOL measures 
of skin-disease burden include utilities 
and willingness to pay.
Structured query. A structured query 
was formulated by the project team 
and validated by the ad hoc consul-
tants. For utility literature, the issues 
queried included whether data were 
empirically derived or developed from 
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population-based instruments, method-
ology of utility elicitation (time trade-off 
or standard gamble or other), popula-
tion interviewed (patients, nonpatients, 
experts), and types of skin diseases. 
For willingness-to-pay literature, the 
issues queried included methodology 
(revealed preference, direct asking), 
variable reported (dollars, percentage 
of income), population interviewed, 
and type of skin diseases.
results
Although theoretically important, 
relatively few large-scale willingness-
to-pay studies have been undertaken 
because accurate and reliable data are 
so difficult to obtain. The task group 
identified 29 studies of skin disease that 
addressed either health-state utilities or 
estimates of willingness to pay. Table 
S3 lists these studies, and the NIAMS 
report provides a summary of findings 
for each study. Of these 29 studies, 12 
derived some kind of health-state util-
ity and another 9 reported a specific 
willingness-to-pay value. Only 7 of the 
health-state utility studies and 1 of the 
willingness-to-pay studies were based 
on patients in the United States.
Of the 12 studies that reported utility 
data, 5 addressed melanoma. However, 
all but two simply assigned util-
ity weights for use in cost-utility mod-
els. Four studies addressed psoriasis; 
however, most authors did not define 
clinical severity. Other clinical enti-
ties studied included acne, foot ulcers, 
and atopic eczema. Chen et al. (2004) 
reported a catalog of time trade-off 
utilities for a variety of skin disorders 
by interviewing 236 patients for 17 
broad skin diseases. The authors dem-
onstrated that utilities can be as low as 
0.64, as found for blistering disorders. 
The mean utility across all skin disor-
ders was 0.943 (s.d. 0.124). Taking a 
much different approach, Cutler and 
Richardson (1997) applied National 
Health Interview Survey data to derive 
a quality-adjusted-life-years weight of 
0.88 for all skin diseases.
For most studies, correlations 
between health-status measures 
and health-state utilities were in the 
expected direction, and many were 
statistically significant. Nevertheless, 
utility values varied with the type of 
utility measure, and the limited num-
ber of patients studied precluded any 
systematic means of determining the 
most appropriate measurement tech-
nique. The dearth of comprehensive 
studies on utilities for skin disease in 
the United States is particularly unfor-
tunate, because of the importance of 
these measures. For example, both 
Cutler and Richardson (1997) and the 
Lewin Group (Bickers et al., 2006) 
attempted to monetize the burden 
of disease by assigning dollar val-
ues to various health states. Although 
these efforts are preliminary, such 
research offers a promising area for 
future assessments of economic values 
of morbidity.
Issues faced by future investigators 
include standardizing disease severities 
and choosing a methodology (empiric 
elicitation vs. population-based instru-
ments, standard gamble vs. time trade-
off, and type of population-based 
instrument). The core group concluded 
that future work investigating the rela-
tionship of these economic QOL mea-




The project team evaluated the appli-
cability of cost-of-illness research to 
our study of the burden of skin disease, 
examining the types of costs included, 
the perspectives of the analyses, and 
the methods of cost accounting used.
Identification of information sourc-
es. The cost burden of skin disease is 
meant to capture the financial burden 
of skin disease on both patients and 
society. Sources of cost information 
were gleaned from both public and pri-
vate databases (see “Epidemiology”), 
as well as from a systematic search of 
published literature.
Although more than 130 articles 
were identified, we found that about 
60 of these studies investigated the 
cost effectiveness of particular drugs or 
procedures, rather than all costs associ-
ated with a particular disease. On sub-
sequent review, we selected 67 articles 
that addressed the cost of one or a set 
of skin diseases. (See Table S4 for a brief 
summary of the economic data con-
tained in each study.) Of these 67 stud-
ies, only 46 developed and presented 
original estimates of the cost of one or 
more skin diseases in the United States.
Structured query for cost studies. 
Items involved in the structured query 
included the purpose of the study, 
whether all or specific skin diseases 
were analyzed, subpopulations (sever-
ity, age groups), data sources, perspec-
tives (patient, payer, societal), methods 
of cost accounting (charge, reimburse-
ment, micro, aggregate), direct costs, 
indirect costs, and other costs such as 
attributable costs from complications.
results
The 46 selected cost studies utilized 
a variety of costing methodologies, 
often relying on several data sources 
and computational techniques within 
the same study. Table S5 displays the 
use distribution of the most frequently 
relied on data sources in the 46 studies. 
Many studies used more than one data 
source, and the majority of the studies 
relied on more than one costing meth-
odology, crafting individual estimat-
ing strategies for each type of medical 
resource (e.g., office visits, hospitals, 
drugs, procedures).
Of the 46 studies, only 5 project-
ed the aggregate or national cost of 
all major skin diseases in the United 
States. These aggregate studies relied 
mostly on public databases, were based 
either directly or indirectly on diag-
nosis codes, and took a limited soci-
etal perspective. None of these studies 
addressed attributable costs. Moreover, 
important differences among scope, 
methodologies, and assumptions made 
comparisons problematic and pro-
duced striking discrepancies among the 
published estimates.
Studies presenting costs for indi-
vidual diseases are similarly nonstan-
dardized. Table S5 displays costs by 
component for each of the 46 stud-
ies reviewed and results found in the 
NIAMS report present a description of 
the cost-related findings of each of the 
individual studies. Comparing these 
studies is precarious, however, because 
of diverging time periods, perspectives, 
and methodologies.
Another concern is that the precision 
of the published cost estimates ultimate-
ly relies on the accuracy of available 
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resource utilization data. Inaccuracies 
in coding and discrepancies in collec-
tion rates, however, limit our confidence 
in the reliability and completeness of 
resource utilization databases. Frequent 
disagreement among published esti-
mates of resource use heightens these 
concerns. In particular, we noted several 
estimates of resource use obtained from 
public databases that differed markedly 
from those obtained from private data-
bases. Although valid reasons exist for 
some differences, a substantial portion 
of the cost discrepancies among stud-
ies results from conflicting estimates of 
resource utilization.
Other methodological problems 
ranged from curtailed perspectives to 
an absence of transparency and a lack 
of analyses of disease complications 
and comorbidities. Among health-care 
researchers, there is a strong preference 
for a societal perspective. Nonetheless, 
many studies adopt narrower view-
points, which yield biased estimates of 
overall cost burdens. The lack of trans-
parency among studies could easily be 
remedied by clearer and more detailed 
presentations or by explicit offers from 
authors to provide additional explana-
tions or supporting data. Finally, the 
general absence of estimates regarding 
the effects of disease complications and 
comorbidities is a vexing problem that 
can be overcome only by painstaking 
research. We cannot even guess what 
impact such directed efforts would 
have on the magnitude of the resulting 
cost estimates. In sum, the substantial 
data gaps and methodological con-
cerns demonstrate that considerable 
work remains before an authoritative 
estimate of the costs of skin disease can 
be developed.
project recommendations
1. Further research and dialogue 
among the dermatology community 
is needed to reach consensus on 
how burden is to be reported. Our 
project conceptualized “burden” as 
three constructs (volume of disease 
or epidemiology, QOL, and cost of 
illness), but others have promoted 
the use of one summary number, 
specifically costs. If the latter 
approach is favored, then further 
research should investigate the 
accurate translation of QOL  
into costs.
2. Further dialogue must also take 
place to reach consensus on how 
to define skin disease. What are 
the criteria by which we choose 
specific skin diseases? Such criteria 
must ensure practicality as well as 
acceptability by the dermatology 
community.
3. A consensus for standardization 
of definitions, methods, and data 
reporting must be reached for 
epidemiology, QOL, and economic 
burden. We proposed developing 
and field testing a compendium 
of standards by which future 
researchers must abide.
4. Additional adult skin-specific QOL 
instruments for the more prevalent 
skin diseases should be developed, 
and these should assess symptoms 
and the functional, psychological, 
social, and emotional impact 
of skin disease. Additionally, 
skin-specific QOL measures for 
children and family impact must 
be developed to understand QOL 
impact more comprehensively. 
These new instruments should 
follow the recommended 
methodological standards  
outlined above.
5. Existing and future databases 
should attempt to capture over-
the-counter drug costs as well as 
indirect costs incurred by both 
patients and families.
6. Once a consensus has been 
achieved on the definition of skin 
disease, existing population survey-
based databases should include 
questions about these diseases in 
order to more accurately capture 
the epidemiology of these diseases.
7. Institutions with electronic 
medical records should consider 
adopting the approach taken by the 
Rochester Epidemiology project, 
in which diagnoses are captured 
according to diagnostic criteria that 
are matched with a comprehensive 
diagnostic medical index. This 
approach ensures accuracy  
and comprehensiveness of 
diagnosis data.
8. Future work should investigate the 
relationship between preference-
based QOL measures and health-
status measures, as well as the 
relationship between willingness to 
pay and utilities. These endeavors, 
if successful, may allow for the 
capture of burden into a summary 
cost measure.
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